Microchimerism in promoting graft acceptance in clinical transplantation

Current Opinion in Organ Transplantation

Volumn 16, Issue 4, 2011, Pages 345-352

  Mathew, James M ^a,b   Leventhal, Joseph R ^a   Miller, Joshua ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

clinical organ transplants; donor stem cells; graft acceptance; immune regulation; microchimerism

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; LEUKOCYTE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MITOGENIC AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ALLOIMMUNITY; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL PROTOCOL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GRAFT REJECTION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY GRAFT; LYMPH NODE IRRADIATION; MICROCHIMERISM; MULTIPLE MYELOMA; MYELOID PROGENITOR CELL; NONHUMAN; ORGAN DONOR; ORGAN TRANSPLANTATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; REVIEW; STEM CELL; TRANSPLANTATION TOLERANCE; X IRRADIATION;

BONE MARROW TRANSPLANTATION; CLONAL DELETION; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION CHIMERA; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

EID: 80051785328     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283489a42     Document Type: Review

References (89)

1. Slavin S, Fuks Z, Strober S, et al. Transplantation tolerance across major histocompatibility barriers after total lymphoid irradiation. Transplantation 1979; 28:359-361. (Pubitemid 10163735)
2. Monaco AP, Wood ML. Studies on heterologous antilymphocyte serum in mice. VII: Optimal cellular antigen for induction of immunologic tolerance with antilymphocyte serum. Transplant Proc 1970; 2:489-496.
3. Caridis DT, Liegeois A, Barrett I, Monaco AP. Enhanced survival of canine renal allografts of ALS-treated dogs given bone marrow. Transplant Proc 1973; 5:671-674.
4. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature 1953; 172:603-606; reprint in J Immunol 2010; 184:5-8.
5. Opelz G, Terasaki PI. Improvement of kidney-graft survival with increased numbers of blood transfusions. N Engl J Med 1978; 299:799-803. (Pubitemid 9044523)
6. Salvatierra O Jr, Vincenti F, Amend W, et al. Deliberate donor-specific blood transfusions prior to living related renal transplantation: A new approach. Ann Surg 1980; 192:543-552. (Pubitemid 11225438)
7. Monaco AP, Clark AW, Wood ML, et al. Possible active enhancement of a human cadaver renal allograft with antilymphocyte serum (ALS) and donor bone marrow: Case report of an initial attempt. Surgery 1976; 79:384-392.
8. Barber WH, Mankin JA, Laskow DA, et al. Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation 1991; 51:70-75.
9. McDaniel DO, Naftilan J, Hulvey K, et al. Peripheral blood chimerism in renal allograft recipients transfused with donor bone marrow. Transplantation 1994; 57:852-856. (Pubitemid 24114676)
10. Starzl TE, Demetris AJ, Trucco M, et al. Cell migration and chimerism after whole-organ transplantation: The basis of graft acceptance. Hepatology 1993; 17:1127-1152. (Pubitemid 23187422)
11. Starzl TE, Demetris AJ, Trucco M, et al. Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation 1993; 55:1272-1277. (Pubitemid 23183236)
12. Fontes P, Rao AS, Demetris AJ, et al. Bone marrow augmentation of donorcell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet 1994; 344:151-155. (Pubitemid 24218877)
13. Ricordi C, Karatzas T, Selvaggi G, et al. Multiple bone marrow infusions to enhance acceptance of allografts from the same donor [review]. Ann N Y Acad Sci 1995; 770:345-350. (Pubitemid 26136308)
14. Garcia-Morales R, Carreno M, Mathew J, et al. The effects of chimeric cells following donor bone marrow infusions as detected by PCR-flow assays in kidney transplant recipients. J Clin Invest 1997; 99:1118-1129. (Pubitemid 27123650)
15. Garcia-Morales R, Carreno M, Mathew J, et al. Continuing observations on the regulatory effects of donor-specific bone marrow cell infusions and chimerism in kidney transplant recipients. Transplantation 1998; 65:956-965. (Pubitemid 28201449)
16. Miller J, Mathew J, Garcia-Morales R, et al. The human bone marrow as an immunoregulatory organ [review]. Transplantation 1999; 68:1079-1090. (Pubitemid 29517691)
17. Ciancio G, Miller J, Garcia-Morales RO, et al. Six-year clinical effect of donor bone marrow infusions in renal transplant patients. Transplantation 2001; 71:827-835. (Pubitemid 32417339)
18. Ciancio G, Burke GW, Garcia-Morales R, et al. Effect of living-related donor bone marrow infusion on chimerism and in vitro immunoregulatory activity in kidney transplant recipients. Transplantation 2002; 74:488-496. (Pubitemid 34977677)
19. Chatzipetrou MA, Mathew JM, Kenyon NS, et al. Analysis of posttransplant immune status in recipients of liver/bone marrow allografts. Hum Immunol 1999; 60:1281-1288. (Pubitemid 30017512)
20. Ciancio G, Burke GW, Moon J, et al. Donor bone marrow infusion in deceased and living donor renal transplantation. Yonsei Med J 2004; 45: 998-1003. (Pubitemid 40136655)
21. Mathew JM, Garcia-Morales RO, Carreno M, et al. Immune responses and their regulation by donor bone marrow cells in clinical organ transplantation. Transpl Immunol 2003; 11:307-321. (Pubitemid 37120550)
22. Cirocco RE, Carreno MR, Mathew JM, et al. FoxP3 mRNA transcripts and regulatory cells in renal transplant recipients 10 years after donor marrow infusion. Transplantation 2007; 83:1611-1619. (Pubitemid 46987914)
23. Gammie JS, Colson YL, Griffith BP, Pham SM. Chimerism and thoracic organ transplantation [review]. Semin Thorac Cardiovasc Surg 1996; 8:149-155.
24. Gammie JS, Pham SM. Simultaneous donor bone marrow and cardiac transplantation: Can tolerance be induced with the development of chimerism? Curr Opin Cardiol 1999; 14:126-132. (Pubitemid 29141361)
25. Salgar SK, Shapiro R, Dodson F, et al. Infusion of donor leukocytes to induce tolerance in organ allograft recipients. J Leukoc Biol 1999; 66:310-314. (Pubitemid 29379175)
26. Mathew JM, Carreno M, Fuller L, et al. Modulatory effects of human donor bone marrow cells on allogeneic cellular immune responses. Transplantation 1997; 63:686-692. (Pubitemid 27132201)
27. Mathew JM, Carreno M, Fuller L, et al. In vitro immunogenicity of cadaver donor bone marrow cells used for the induction of allograft acceptance in clinical transplantation. Transplantation 1999; 68:1172-1180. (Pubitemid 29517708)
28. Mathew JM, Carreno M, Zucker K, et al. Cellular immune responses of human cadaver donor bone marrow cells and their susceptibility to commonly used immunosuppressive drugs in transplantation. Transplantation 1998; 65:947-955. (Pubitemid 28201448)
29. Mathew JM, Fuller L, Carreno M, et al. Involvement of multiple subpopulations of human bone marrow cells in the regulation of allogeneic cellular immune responses. Transplantation 2000; 70:1752-1760. (Pubitemid 32064831)
30. Mathew JM, Carreno M, Fuller L, et al. Regulation of alloimmune responses (GvH reactions) in vitro by autologous donor bone marrow cell preparation used in clinical organ transplantation. Transplantation 2002; 74:846-855.
31. Lagoo-Deenadayalan S, Lagoo AS, Lemons JA, et al. Donor specific bone marrow cells suppress lymphocyte reactivity to donor antigens and differentially modulate TH1 and TH2 cytokine gene expression in the responder cell population. Transpl Immunol 1995; 3:124-134.
32. Rachamim N, Gan J, Segall H, et al. Tolerance induction by 'megadose' hematopoietic transplants: Donor-type human CD34 stem cells induce potent specific reduction of host antidonor cytotoxic T lymphocyte precursors in mixed lymphocyte culture. Transplantation 1998; 65:1386-1393.
33. Schlitt HJ, Kanehiro H, Raddatz G, et al. Persistence of donor lymphocytes in liver allograft recipients. Transplantation 1993; 56:1001-1007. (Pubitemid 23321544)
34. Ayala R, Grande S, Albizua E, et al. Long-term follow-up of donor chimerism and tolerance after human liver transplantation. Liver Transpl 2009; 15:581-591.
35. Jonsson JR, Hogan PG, Thomas R, et al. Peripheral blood chimerism following human liver transplantation. Hepatology 1997; 25:1233-1236. (Pubitemid 27199953)
36. Spitzer TR, Delmonico F, Tolkoff-Rubin N, et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: The induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999; 68:480-484. (Pubitemid 29416620)
37. Fudaba Y, Spitzer TR, Shaffer J, et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: In vivo and in vitro analyses. Am J Transplant 2006; 6:2121-2133. (Pubitemid 44199546)
38. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358:353-361. (Pubitemid 351159234)
39. LoCascio SA, Morokata T, Chittenden M, et al. Mixed chimerism, lymphocyte recovery, and evidence for early donor-specific unresponsiveness in patients receiving combined kidney and bone marrow transplantation to induce tolerance. Transplantation 2010; 90:1607-1615.
40. Millan MT, Shizuru JA, Hoffmann P, et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation 2002; 73:1386-1391. (Pubitemid 34547457)
41. Strober S, Busque S, Dejbakhsh-Jones S, et al. Inducing tolerance in clinical kidney transplantation [abstract]. Transplantation 2010; 90 (2S):323.
42. Trivedi H, Shah V, Shah P, et al. High dose DBMC associated tolerance in liverelated renal allograft recipients. Transplant Proc 2000; 32:2001-2002.
43. Trivedi H, Vanikar A, Shah V, et al. Mega dose unfractionated donor bone marrow-derived cell infusion in thymus and periphery: An integrated clinical approach for tolerance in living related renal allografts. Transplant Proc 2003; 35:203-206. (Pubitemid 36194573)
44. Trivedi HL, Terasaki PI, Feroz A, et al. Clonal deletion with Bortezomib followed by low or no maintenance immunosuppression in renal allograft recipients. Transplantation 2010; 90:221-222.
45. Miller J, Leventhal J, Gallon L, et al. Donor specific immunoregulation in HLAidentical renal transplant recipients given Alemtuzimab and donor stem cells. Transplantation 2010; 90:234.
46. Leventhal J, Gallon L, Miller J, et al. Induction of donor specific tolerance in recipients of HLA disparate living donor kidney allografts by donor stem cell infusion [abstract 2660]. Transplantation 2010; 90:465.
47. Leventhal JR, Gallon L, Miller J, et al. Facilitating cell enriched stem cell infusion results in durable chimerism, donor specific tolerance, and allows for immunosuppressive drug withdrawal in recipients of HLA disparate living donor kidney allografts [abstract 3375]. Transplantation 2010; 90:183.
48. Kaufman C, Colson Y, Wren S, et al. Phenotypic characterization of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells. Blood 1994; 84:2436-2446. (Pubitemid 24317373)
49. Ildstad ST, Crilley PA, Kaufman CL, et al. Graft engineering (II): A multivariate analysis of the facilitating cell protocol in advanced hematologic malignancy for mismatched donors [abstract]. In: Annual Meeting of the American Society of Hematology; New Orleans, LA; 6 December 1999.
50. Ildstad ST, Crilley PA, Kaufman CL, et al. A graft engineering method to allow bone marrow transplantation (BMT) for more highly mismatched recipients with leukemia: Multivariate analysis of a phase I/II protocol [abstract]. In: Transplant 2000, American Society of Transplant Surgeons and American Society of Transplantation; Chicago, IL; 13-17 May 2000.
51. Ravindra K, Herzig R, Paris K, et al. Donor marrow infusion in kidney transplantation: Results of preliminary study [abstract]. Am J Transplant 2008; 8 (Suppl 2):214.
52. Anderson D, Billingham RE, Lampkin GH, Medawar PB. The use of skin grafting to distinguish between monozygotic and dizygotic twins in cattle. Heredity 1952; 6:201-221.
53. Owen RD. Immunogenetic consequences of vascular anastomoses between bovine twins. Science 1945; 102:400-401.
54. Drexler C, Wagner T. Blood group chimerism [review]. Curr Opin Hematol 2006; 13:484-489.
55. Sivasai KS, Alevy YG, Duffy BF, et al. Peripheral blood microchimerism in human liver and renal transplant recipients: Rejection despite donor-specific chimerism. Transplantation 1997; 64:427-432 [erratum appears in Transplantation 1997; 64:1636]. (Pubitemid 27349882)
56. Schlitt HJ, Hundrieser J, Ringe B, Pichlmayr R. Donor-type microchimerism associated with graft rejection eight years after liver transplantation [letter]. N Engl J Med 1994; 330:646-647. (Pubitemid 24065809)
57. van Tol MJ, Langlois van den Bergh R, Mesker W, et al. Simultaneous detection of X and Y chromosomes by two-colour fluorescence in situ hybridization in combination with immunophenotyping of single cells to document chimaerism after sex-mismatched bone marrow transplantation. Bone Marrow Transplant 1998; 21:497-503. (Pubitemid 28107957)
58. Pei R, Chen T, Orpilla J, Lee JH. A simultaneous negative and positive selection method that can detect chimerism at a frequency of 1 per 10,000 by flow cytometry. Tissue Antigens 1997; 50:197-201. (Pubitemid 27326286)
59. Garcia-Morales R, Esquenazi V, Zucker K, et al. An assessment of the effects of cadaver donor bone marrow on kidney allograft recipient blood cell chimerism by a novel technique combining PCR and flow cytometry. Transplantation 1996; 62:1149-1160. (Pubitemid 26376667)
60. Gineikiene E, Stoskus M, Griskevicius L. Recent advances in quantitative chimerism analysis [review]. Expert Rev Mol Diagn 2009; 9:817-832.
61. Sahota A, Gao S, Hayes J, Jindal RM. Microchimerism and rejection: A metaanalysis. Clin Transplant 2000; 14 (4 Pt 1):345-350.
62. Saraji A, Pourmand G,Mehrsai A, et al. Microchimerism and renal transplantation: Doubt still persists. Transplant Proc 2007; 39:948-950. (Pubitemid 46764908)
63. Elwood ET, Larsen CP, Maurer DH, et al. Microchimerism and rejection in clinical transplantation. Lancet 1997; 349:1358-1360. (Pubitemid 27197538)
64. SivaSai KS, Jendrisak M, Duffy BF, et al. Chimerism in peripheral blood of sensitized patients waiting for renal transplantation: Clinical implications. Transplantation 2000; 69:538-544. (Pubitemid 30129586)
65. Pollack MS, Speeg KV, Callander NS, et al. Severe, late-onset graft-versushost disease in a liver transplant recipient documented by chimerism analysis. Hum Immunol 2005; 66:28-31. (Pubitemid 40037708)
66. Zhang Y, Ruiz P. Solid organ transplant-associated acute graft-versus-host disease [review]. Arch Pathol Lab Med 2010; 134:1220-1224.
67. Mathew JM, Garcia-Morales R, Fuller L, et al. Donor bone marrow-derived chimeric cells present in renal transplant recipients infused with donor marrow. I: Potent regulators of recipient antidonor immune responses. Transplantation 2000; 70:1675-1682. (Pubitemid 32064819)
68. Mathew JM, Ciancio G, Burke GW, et al. Immune 'tolerance profiles' in donor bone marrow infused kidney transplant patients using multiple ex vivo functional assays. Hum Immunol 2010; 71:566-576. This study suggests that patients who have achieved donor-specific unresponsiveness in a cluster analysis combining multiple immune assays are possible candidates for immunosuppression minimization, and such a condition appears to have occurred in many immunosuppressed donor bone marrow cell infused renal transplant recipients.
69. Austyn JM, Larsen CP. Migration patterns of dendritic leukocytes. Implications for transplantation [review]. Transplantation 1990; 49:1-7. (Pubitemid 20051573)
70. Larsen CP, Austyn JM, Morris PJ. The role of graft-derived dendritic leukocytes in the rejection of vascularized organ allografts. Recent findings on the migration and function of dendritic leukocytes after transplantation. Ann Surg [review] 1990; 212:308-315; discussion 316-317.
71. Ringden O, Soderdahl G, Mattsson J, et al. Transplantation of autologous and allogeneic bone marrow with liver from a cadaveric donor for primary liver cancer. Transplantation 2000; 69:2043-2048. (Pubitemid 30395031)
72. Nierhoff D, Horvath HC, Mytilineos J, et al. Microchimerism in bone marrowderived CD34(+) cells of patients after liver transplantation. Blood 2000; 96:763-767. (Pubitemid 30463403)
73. Starzl TE. Chimerism and tolerance in transplantation [review]. Proc Natl Acad Sci U S A 2004; 101 (Suppl 2):14607-14614.
74. Rugeles MT, Aitouche A, Zeevi A, et al. Evidence for the presence of multilineage chimerism and progenitors of donor dendritic cells in the peripheral blood of bone marrow-augmented organ transplant recipients. Transplantation 1997; 64:735-741. (Pubitemid 27407102)
75. Moroso V, Metselaar HJ, Mancham S, et al. Liver grafts contain a unique subset of natural killer cells that are transferred into the recipient after liver transplantation. Liver Transpl 2010; 16:895-908.
76. Burlingham WJ, Grailer AP, Fechner JH Jr, et al. Microchimerism linked to cytotoxic T lymphocyte functional unresponsiveness (clonal anergy) in a tolerant renal transplant recipient. Transplantation 1995; 59:1147-1155.
77. Demirkiran A, Bosma BM, Kok A, et al. Allosuppressive donor CD4+CD25+ regulatory T cells detach from the graft and circulate in recipients after liver transplantation. J Immunol 2007; 178:6066-6072. (Pubitemid 46717386)
78. Game DS, Hernandez-Fuentes MP, Chaudhry AN, Lechler RI. CD4+CD25+ regulatory T cells do not significantly contribute to direct pathway hyporesponsiveness in stable renal transplant patients. J Am Soc Nephrol 2003; 14:1652-1661. (Pubitemid 36687069)
79. Kreijveld E, Koenen HJPM, Klasen IS, et al. Following anti-CD25 treatment, a functional CD4+CD25+ regulatory T-cell pool is present in renal transplant recipients. Am J Transplant 2007; 7:249-255. (Pubitemid 44952880)
80. Sewgobind VDKD, van der Laan LJW, Klepper M, et al. Functional analysis of CD4+ CD25bright T cells in kidney transplant patients: Improving suppression of donor-directed responses after transplantation. Clin Transplant 2008; 22:579-586.
81. Baan CC, Velthuis JHL, van Gurp EAFJ, et al. Functional CD25(bright+) alloresponsive T cells in fully immunosuppressed renal allograft recipients. Clin Transplant 2007; 21:63-71. (Pubitemid 46189589)
82. Levitsky J, Miller J, Leventhal J, et al. The human 'Treg MLR': Immune monitoring for FOXP3+ T regulatory cell generation. Transplantation 2009; 88:1303-1311.
83. Levitsky J, Gallon L, Miller J, et al. Allospecific regulatory effects of sirolimus and tacrolimus in the human mixed lymphocyte reaction. Transplantation 2011; 91:199-206.
84. Kean LS, Gangappa S, Pearson TC, Larsen CP. Transplant tolerance in nonhuman primates: Progress, current challenges and unmet needs [review]. Am J Transplant 2006; 6 (5 Pt 1):884-893. (Pubitemid 44356638)
85. Chauhan B, Mathew JM, Shenoy S, et al. Donor human leukocyte antigens in the circulation of liver allograft recipients. Clin Transplant 1995; 9:14-19.
86. Sagoo P, Perucha E, Sawitzki B, et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 2010; 120:1848-1861.
87. Newell KA, Asare A, Kirk AD, et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010; 120:1836-1847.
88. Pallier A, Hillion S, Danger R, et al. Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int 2010; 78:503-513.
89. Mathew JM, Miller J. Immunoregulatory role of chimerism in clinical organ transplantation. Bone Marrow Transplant 2001; 28:115-119. (Pubitemid 32725711)